Immunological assessment of SARS-CoV-2 in IENIMINI cohort individuals with influenza like symptoms.

Recruiting

• Conditions: COVID19; infection caused by SARS-CoV-2 virus; 10003816; 10047438

• Registration Number: NL-OMON54879
• Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 2022-01-04
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 560

Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all
of the following criteria:
- 18 years or older
- participant of the IENIMINI cohort
- reported influenza like symptoms in March-November 2020

Exclusion Criteria

No participant of the IENIMINI study.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is the seroprevalence of COVID19 in patients with an<br /><br>IMID & control persons who experienced influenza like symptoms in<br /><br>March-November 2020. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary parameter is the difference between percentage of people with<br /><br>antibodies against COVID19 who experienced severe symptoms versus only mild<br /><br>symptoms. </p><br>